Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03673501 · ClinicalTrials.gov registry record · Phase 3
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
A Phase 3 study of Gastrointestinal Stromal Tumors, sponsored by Deciphera Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 453
- Enrollment target
- 20
- Study locations
NCT03673501 is a Phase 3 study of Gastrointestinal Stromal Tumors that is active but no longer recruiting, run by Deciphera Pharmaceuticals. The registered enrollment target is 453 participants, above the 50-participant average among 10 other Gastrointestinal Stromal Tumors trials with a reported enrollment target (806% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT03673501, a Phase 3 study of Gastrointestinal Stromal Tumors, is active but no longer recruiting, sponsored by Deciphera Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 453 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).
Conditions Studied
Interventions
- DRUG Sunitinib
- DRUG Ripretinib
Study Locations (20)
Florida
- Mayo Clinic Florida - Jacksonville
- Sylvester Comprehensive Cancer Center - Miami
- Miami Cancer Institute at Baptist Health, Inc. - Miami
- Orlando Health UF Health Cancer Center - Orlando
- Moffitt Cancer Center - Tampa
California
- University of California San Diego Medical Center - La Jolla
- UCLA Hematology Oncology Center - Main Site - Los Angeles
- Stanford Medicine - Stanford
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavillion - Aurora
- Rocky Mountain Cancer Centers - Denver
Georgia
- Winship Cancer Institute - Atlanta
- Georgia Cancer Specialists - Sandy Springs
Illinois
- Northwestern Memorial Hospital - Chicago
- University of Chicago Medical Center - Chicago
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Connecticut
- Smilow Cancer Hospital at Yale - New Haven
District of Columbia
- Washington Cancer Institute at MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2019-02-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03673501
The ClinicalTrials.gov registry entry for NCT03673501 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 453 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 50-participant average among 10 other Gastrointestinal Stromal Tumors trials with a reported enrollment target (806% higher). The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Stromal Tumors appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.
NCT03673501 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03673501 about?
NCT03673501 is a clinical study titled "A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib". This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretin...
What is the current status of trial NCT03673501?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 453 participants. The study started on 2019-02-08. Estimated completion is 2026-12.
What conditions does trial NCT03673501 study?
This clinical trial studies the following conditions: Gastrointestinal Stromal Tumors.
What interventions are being tested in trial NCT03673501?
The interventions under investigation include: Sunitinib (DRUG), Ripretinib (DRUG).
Who is sponsoring clinical trial NCT03673501?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03673501 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Stromal Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
COMPLETED · Phase 3
-
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
RECRUITING · Phase 2
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Integrated Cancer Repository for Cancer Research
RECRUITING
-
Imatinib TDM in GIST
RECRUITING · Phase 2
-
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.